A Brief History of the Treatment of Viral Hepatitis C

Overview

Journal Clin Liver Dis (Hoboken)

Specialty Gastroenterology

Date 2019 Jun 13

PMID 31186837

Citations 12

Authors

Doris B Strader

Leonard B Seeff

Affiliations

Soon will be listed here.

Citing Articles

Association Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus Treatment.

Haque L, Fiellin D, Tate J, Esserman D, Bhattacharya D, Butt A JAMA Netw Open. 2022; 5(12):e2246604.

PMID: 36515952 PMC: 9856353. DOI: 10.1001/jamanetworkopen.2022.46604.

Safety of direct acting antiviral treatment for hepatitis C in oncologic setting: A clinical experience and a literature review.

Spera A World J Hepatol. 2022; 14(3):525-534.

PMID: 35582286 PMC: 9055195. DOI: 10.4254/wjh.v14.i3.525.

Hepatitis C Positive Organ Donation in Heart Transplantation.

Siddiqi H, Schlendorf K Curr Transplant Rep. 2021; 8(4):359-367.

PMID: 34786324 PMC: 8579730. DOI: 10.1007/s40472-021-00350-1.

Drug-Drug Interactions of Newly Approved Direct-Acting Antiviral Agents in Patients with Hepatitis C.

Gao L, Nie Q, Zhao X Int J Gen Med. 2021; 14:289-301.

PMID: 33536776 PMC: 7850569. DOI: 10.2147/IJGM.S283910.

Success of Direct-Acting, Antiviral-Based Therapy for Chronic Hepatitis C Is Not Affected by Type 2 Diabetes.

Niccum B, Stine J, Wynter J, Kelly V, Caldwell S, Shah N Clin Diabetes. 2020; 38(1):40-46.

PMID: 31975750 PMC: 6969670. DOI: 10.2337/cd18-0112.

References

Christensson B, Wiebe T, Akesson A, Widell A . Interferon-alpha and ribavirin treatment of hepatitis C in children with malignancy in remission. Clin Infect Dis. 2000; 30(3):585-6. DOI: 10.1086/313709. View

Zeuzem S, Feinman S, Rasenack J, Heathcote E, Lai M, Gane E . Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000; 343(23):1666-72. DOI: 10.1056/NEJM200012073432301. View

Reddy K, Wright T, Pockros P, Shiffman M, EVERSON G, Reindollar R . Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology. 2001; 33(2):433-8. DOI: 10.1053/jhep.2001.21747. View

Perrillo R . Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology. 2001; 120(4):1009-22. DOI: 10.1053/gast.2001.22461. View

Lindsay K, Trepo C, Heintges T, Shiffman M, Gordon S, Hoefs J . A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 2001; 34(2):395-403. DOI: 10.1053/jhep.2001.26371. View

Manns M, McHutchison J, Gordon S, Rustgi V, Shiffman M, Reindollar R . Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358(9286):958-65. DOI: 10.1016/s0140-6736(01)06102-5. View

Buti M, Sanchez-Avila F, Lurie Y, Stalgis C, Valdes A, Martell M . Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Hepatology. 2002; 35(4):930-6. DOI: 10.1053/jhep.2002.32150. View

Crippin J, McCashland T, Terrault N, Sheiner P, Charlton M . A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl. 2002; 8(4):350-5. DOI: 10.1053/jlts.2002.31748. View

Fried M, Shiffman M, Reddy K, Smith C, Marinos G, Goncales Jr F . Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347(13):975-82. DOI: 10.1056/NEJMoa020047. View

10.

Wirth S, Lang T, Gehring S, Gerner P . Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C. Hepatology. 2002; 36(5):1280-4. DOI: 10.1053/jhep.2002.36495. View

11.

Layden-Almer J, Ribeiro R, Wiley T, Perelson A, Layden T . Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology. 2003; 37(6):1343-50. DOI: 10.1053/jhep.2003.50217. View

12.

Bruchfeld A, Lindahl K, Stahle L, Soderberg M, Schvarcz R . Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant. 2003; 18(8):1573-80. DOI: 10.1093/ndt/gfg209. View

13.

Davis G, Wong J, McHutchison J, Manns M, Harvey J, Albrecht J . Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology. 2003; 38(3):645-52. DOI: 10.1053/jhep.2003.50364. View

14.

CHALMERS T, REYNOLDS W, ECKHARDT R, CIGARROA J, Deane N, REIFENSTEIN R . Treatment of acute infectious hepatitis in the Armed Forces; advantages of ad lib. bed rest and early reconditioning. J Am Med Assoc. 1955; 159(15):1431-4. DOI: 10.1001/jama.1955.02960320007003. View

15.

HUBER T, WILEY A . Cortisone in the treatment of infectious hepatitis. Ann Intern Med. 1955; 42(5):1011-25. DOI: 10.7326/0003-4819-42-5-1011. View

16.

Hadziyannis S, Sette Jr H, Morgan T, Balan V, Diago M, Marcellin P . Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004; 140(5):346-55. DOI: 10.7326/0003-4819-140-5-200403020-00010. View

17.

Jeffers L, Cassidy W, Howell C, Hu S, Reddy K . Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology. 2004; 39(6):1702-8. DOI: 10.1002/hep.20212. View

18.

Torriani F, Rodriguez-Torres M, Rockstroh J, Lissen E, Gonzalez-Garcia J, Lazzarin A . Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004; 351(5):438-50. DOI: 10.1056/NEJMoa040842. View

19.

Chung R, Andersen J, Volberding P, Robbins G, Liu T, Sherman K . Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004; 351(5):451-9. PMC: 4113392. DOI: 10.1056/NEJMoa032653. View

20.

Sugawara Y, Makuuchi M, Matsui Y, Kishi Y, Akamatsu N, Kaneko J . Preemptive therapy for hepatitis C virus after living-donor liver transplantation. Transplantation. 2004; 78(9):1308-11. DOI: 10.1097/01.tp.0000142677.12473.e5. View